KUALA LUMPUR, July 31 (Bernama) -- Taconic Biosciences, a drug discovery animal model solution provider has launched its first diet-induced non-alcoholic steatohepatitis (NASH) rodent model.
Commercially available, NASH is a dangerous sub-type of non-alcoholic fatty liver disease (NAFLD) and recently garnered increased attention in the biomedical community due to its growing prevalence in the population.
With some diet-induced models requiring up to 26 weeks to become ready for study, time delays are a serious problem for drug discovery.
Additionally, the absence of a commercial product forces researchers to use their precious vivarium space to condition animals for months, displacing other important projects.
Taconic commercial model portfolio vice-president, Dr Michael Seiler said: “Helping researchers save months is a great example of how Taconic is constantly working to provide our customers with the best animal model solutions.”
Taconic boasts a strong history providing animal models to aid in metabolic syndrome research, including the first diet-induced obesity model and the industry’s most comprehensive microbiome solution platform.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, between 30 and 40 per cent of adults in the United States are afflicted with NAFLD while between three and 12 per cent have NASH.
-- BERNAMA
No comments:
Post a Comment